drugset / Trial / NCT05681351
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Timeline
- Start
- 2022-12-13
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olezarsen | Antisense oligonucleotide | — | Subcutaneous |
Indications
No indication recorded.